对于没有其他治疗选择的胰腺神经内分泌肿瘤患者，依维莫司再次治疗的临床结果

Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options.

作者信息

Kurita Yusuke, Kobayashi Noritoshi, Hara Kazuo, Mizuno Nobumasa, Kuwahara Takamichi, Okuno Nozomi, Haba Shin, Tokuhisa Motohiko, Hasegawa Sho, Kubota Kensuke, Nakajima Atsushi, Ichikawa Yasushi

机构信息

Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama 236-0004, Japan.

Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan.

出版信息

Cancers (Basel). 2022 Nov 18;14(22):5669. doi: 10.3390/cancers14225669.

DOI:10.3390/cancers14225669

PMID:36428761

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9688517/

Abstract

BACKGROUND

The clinical outcomes of everolimus rechallenge in patients with pancreatic neuroendocrine neoplasms (PNENs) are unknown. This study aimed to investigate the treatment outcomes and safety of everolimus rechallenge treatment with PNENs.

METHODS

Clinical data of everolimus-treated patients with PNENs at two institutions were collected. Patients who underwent everolimus rechallenge were included in the study. We analyzed the progression-free survival (PFS) and treatment response associated with everolimus rechallenge and the adverse events.

RESULTS

Between 2008 and 2020, 117 patients received initial treatment with everolimus, of which 14 patients received everolimus rechallenge. With regard to the grade of PNENs, there were 2 cases of G1, 11 cases of G2, and 1 case of G3. The median rechallenge PFS was 5.7 months. The objective response rate was 21.4%. the disease control rate was 71.4%. The only major grade 3 or 4 adverse event was neutropenia ( = 1, 7.1%). No other severe adverse event was observed.

CONCLUSION

The outcomes and safety of everolimus rechallenge were verified, and it was deemed an acceptable treatment. Everolimus rechallenge may provide a new drug therapy for patients with advanced PNENs for whom no other drug treatment option is available.

摘要

背景

胰腺神经内分泌肿瘤（PNENs）患者再次使用依维莫司治疗的临床结局尚不清楚。本研究旨在调查PNENs患者再次使用依维莫司治疗的疗效和安全性。

方法

收集了两家机构接受依维莫司治疗的PNENs患者的临床数据。纳入接受依维莫司再次治疗的患者。我们分析了与依维莫司再次治疗相关的无进展生存期（PFS）、治疗反应和不良事件。

结果

2008年至2020年期间，117例患者接受了依维莫司初始治疗，其中14例患者接受了依维莫司再次治疗。关于PNENs的分级，G1级2例，G2级11例，G3级1例。再次治疗的中位PFS为5.7个月。客观缓解率为21.4%，疾病控制率为71.4%。唯一主要的3级或4级不良事件是中性粒细胞减少（n = 1，7.1%）。未观察到其他严重不良事件。